| Document |
Document Title |
|
WO/2020/053256A1 |
The present disclosure relates to imaging and endoradiotherapy of diseases involving chemokine receptor 4 (CXCR4). Provided are compounds which bind or inhibit hCXCR4 and mCXCR4 and furthermore carry at least one moiety which is amenable...
|
|
WO/2020/055951A1 |
The present invention provides positron emitter radiolabeled versions of PABA, metabolites and derivatives, with good radiochemical yield, high specific activity, high chemical and radiochemical purity and having excellent characteristic...
|
|
WO/2020/056064A1 |
Methods and compositions for treating, diagnosing and staging cancers, in particular overexpressing the Human Epidermal growth factor Receptor 2 protein (HER2+) given rise to in breast, gastric, gastroesophageal, ovarian, pancreatic canc...
|
|
WO/2020/050419A1 |
The present invention provides a cyclic peptide which has a unit structure selected from among the structures represented by formula (1) -X1-X2-X3-X4-X5-, or a pharmaceutically acceptable salt of the cyclic peptide. (In formula (1), X1 r...
|
|
WO/2020/051549A1 |
The present invention provides peptides and peptide-conjugates that bind to α νβ6integrin. The peptide-conjugates can be used for a variety of imaging and therapeutic applications. Methods of use and peptide optimization are also prov...
|
|
WO/2020/050782A1 |
The innovative combination of the various biological agents has enabled the development of various treating forms either for osteoporosis or for osteoarthritis or for the rapidity of fracture rehabilitation, in various forms. This treatm...
|
|
WO/2020/051032A1 |
The present technology relates to nanomaterials and methods of their use, and more specifically to methods and structures using nanomaterials to fiducially measure radiation dosing.
|
|
WO/2020/049300A1 |
A method for the early detection and monitoring of the progression of cancer by detecting breath biomarkers is provided. The method comprises assessing the activity of an aldo-keto reductase by measuring the concentration of an exogenous...
|
|
WO/2020/045638A1 |
The present invention provides a radiolabeled compound represented by formula (1), which is a radioactive imidazothiadiazole derivative compound having affinity for CA-IX, and salts thereof. In formula (1), n is an integer of 1 to 4 and ...
|
|
WO/2020/043617A1 |
The present invention relates to combinations of at least two components, component A and component B, component A being an inhibitor of PI3K kinase, and component B being a targeted thorium conjugate. Another aspect of the present inven...
|
|
WO/2020/045816A1 |
The present invention relates to a blood-brain barrier (BBB)-permeable aptamer and an application thereof to a complex in which a material selectively binding to a target material present in the brain is conjugated therewith. The aptamer...
|
|
WO/2020/041626A1 |
Affibody polypeptides that specifically bind to B7-H3 are provided. Exemplary anti-B7-H3 affibodies are provided. The affibody polypeptides specifically recognize and bind to B7-H3 with high affinity. The affibodies can be conjugated to ...
|
|
WO/2020/039962A1 |
The present invention provides a solution which is for improving the stability of a precursor compound for a radioactive fluorine-labeled compound, and in which a compound represented by formula (2) or a salt thereof is stored in a state...
|
|
WO/2020/033200A1 |
A composition of a bilirubin stock and a method of preparation are provided. In one aspect of the invention, the composition includes a base solution. The composition further includes a carbonate salt. Additionally, the composition inclu...
|
|
WO/2020/031136A1 |
The invention relates to the field of medicine and molecular biology and may be used for long-lasting therapy of cancer with adjuvant effect using SANPs-theranostics (SANPs – self assembled nano particles). A composition of self assemb...
|
|
WO/2020/030827A1 |
The present invention provides antibodies that bind human Anx-A1 for use in the treatment of cancer, including drug-resistant cancer. Kits and products for this use are also provided.
|
|
WO/2020/033523A1 |
This disclosure relates to methods of determining if a subject not manifesting any clinical symptoms of a dopaminergic disorder is afflicted with the dopaminergic disorder using radiolabeled DatT020 or a derivative thereof.
|
|
WO/2019/003202A9 |
A method of obtaining, from a target compound, a radioisotope of a target element comprised in the target compound includes irradiating the target compound with high energy photon irradiation (gamma irradiation). Thereby the target eleme...
|
|
WO/2020/032038A1 |
The present invention provides a compound represented by formula (I), which has high specificity and high selectivity for monoamine oxidase B, and which is capable of imaging monoamine oxidase B with a good sensitivity, or a pharmaceutic...
|
|
WO/2020/033521A1 |
The present application provides polymer materials having the desired properties for implantation into a human or animal body, in particular, biocompatibility, biodegradability, radiopacity and mechanical properties. Methods of making su...
|
|
WO/2020/030954A1 |
The invention relates to the field of medicine and molecular biology and may be used for long-lasting therapy of prostate cancer with adjuvant effect using SANPs-theranostics (SANPs – self assembled nano particles). A composition of se...
|
|
WO/2020/028323A1 |
Methods for co-injection of a non-radioactive PSMA inhibitor, referred to herein as a competing inhibitor (CI), with a radiolabeled PSMA inhibitor are disclosed. This combination reduces the uptake of the radiotracer in non-target organs...
|
|
WO/2020/028825A1 |
Disclosed herein are methods preparing a purified, carrier-free 68Ga solution. Tire present disclosure also provides systems for preparing a purified, carrier-free 68Ga solution. The present disclosure also provides compositions comprisi...
|
|
WO/2020/023247A1 |
The present disclosure provides albumin-binding radioactive metal complexes and uses thereof, including diagnosing and treating disease.
|
|
WO/2020/022765A1 |
The present invention relates to a neovascular-targeting contrast medium composition and a method for preparing same. The neovascular-targeting contrast medium composition according to the present invention exhibits high binding force to...
|
|
WO/2020/021465A1 |
The present invention relates to methods of treating cancers that overexpress somatostatin receptors, e.g. neuroendocrine tumors (NET). In particular, the invention provides novel therapies based on the combination of a peptide receptor ...
|
|
WO/2020/023306A1 |
A novel fluorophore based on an acid soluble reagent that is a lanthanide metal ion nanoparticle that is passivated and/or coated for water dispersion and to minimize nonspecific binding, and assays for same
|
|
WO/2020/021322A1 |
The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is ...
|
|
WO/2020/021310A1 |
The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is ...
|
|
WO/2020/023092A2 |
Alpha-emitting LIPIODOL® emulsions and their use in treating cancer is disclosed. Radionuclides, including, but not limited to actinium-225 and bismuth-212/lead-212, are incorporated in LIPIODOL® emulsions. The alpha-emitting LIPIODOLÂ...
|
|
WO/2020/017557A1 |
Provided are: a compound suitable for imaging an intracerebral TRPV1 receptor; and a use thereof. A compound or a salt thereof represented by formula (I) is used. [In formula (1), R1 is a hydrogen or a random organic group; R2 is an orga...
|
|
WO/2020/018743A1 |
Disclosed is a method of increasing the rate of delivery of an active compound or agent to the brain across the blood brain barrier of a subject. In one aspect, the disclosure provides an accelerated method of providing an active compoun...
|
|
WO/2020/016561A1 |
Compounds are presented having the formula [M4L6].Xn, where M is a transition metal ion having 6 d-shell valence electrons, X is a counter ion and n is the number of counterions such that the total charge of the compound of formula (I) i...
|
|
WO/2020/013879A1 |
A method for treating a cancer comprises administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising an anti-cancer agent having at least one secretion modifying region (SMR) peptid...
|
|
WO/2020/009093A1 |
Provided are: a CXCR4-binding compound having high accumulation in tumors that express CXCR4; and a treatment agent for diagnosis or therapy, etc., having the compound as an active ingredient. A compound represented by general formula (1...
|
|
WO/2020/009945A1 |
Site-selective conjugation to biomolecules via thiol-based chemistry is superior to the unselective modification of lysine residues, which produce a mixed product and can potentially interfere with binding affinity of the biomolecule. Ho...
|
|
WO/2020/007893A1 |
The present invention refers to reagents and methods for preparing a peptide sequence having a [18F]fluoro-aromatic amino acid side which may be further substituted, in particular a 4-[18F]fluoro-phenylalanine side chain in peptide seque...
|
|
WO/2020/002459A1 |
There is provided novel polypeptide-based carrier systems, which make it possible to label polymeric nanoparticles in the living organism. This enables new approaches in tumor diagnostics (high signal to background ratio) and radiotherap...
|
|
WO/2020/002314A1 |
The present invention relates to a compound of formula (I) wherein R1, R2, and R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a radiolabeled ligand.
|
|
WO/2020/004490A1 |
The present invention relates to: an antibody or a fragment of said antibody that binds to chondroitin sulfate proteoglycan-5 (CSPG5); a hybridoma that produces the antibody or the antibody fragment; a nucleic acid that contains a base s...
|
|
WO/2020/003153A1 |
A liquid composition comprising a polymer having pendant groups of the formula I: (I) Wherein X is either a bond or is a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N and S; and n is 1 to 4.
|
|
WO/2020/004785A1 |
The present invention relates to a radioactive compound with an improved ability to target melanoma, and a pharmaceutical composition for treating melanoma comprising same. Compared to conventional compositions for contrasting melanoma, ...
|
|
WO/2020/006445A1 |
The present disclosure relates to methods, compositions, and kits for treating traumatic brain injury (TBI) and TBI-associated impairments in a subject. The methods include administering to the subject an interleukin-7 (IL-7) or IL-7 ago...
|
|
WO/2020/006075A1 |
Positron emission tomography (PET) radiotracers for imaging macrophage colony stimulating factor-1 receptors in a subject afflicted with or suspected of being afflicted with a neuroinflammatory or neurodegenerative disease or disorder ar...
|
|
WO/2020/004656A1 |
Provided is a rare earth complex which comprises one or more trivalent rare earth ions and a plurality of ligands coordinating to the rare earth ions. The plurality of ligands includes: a first ligand which has a carborane group and a co...
|
|
WO/2019/246311A1 |
The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications. In various embodiments, the invention described herein pertains to the diagnosis, imaging, and/or treatment of pathoge...
|
|
WO/2019/243419A1 |
The present disclosure relates to a solution comprising a water insoluble carbohydrate and a radionuclide chelated by a hydrophobic chelator, wherein the solution sets under aqueous conditions, such as in vivo, to form e.g. a gel, a semi...
|
|
WO/2019/244954A1 |
The purpose of the present invention is to provide a 10B medicine that can be selectively accumulated in tumor tissues at a low dose in a short time, and can be applied to BNCT. The accumulative 10B medicine comprises a compound containi...
|
|
WO/2019/243489A1 |
The present invention relates to a somatostatin analogue composition for radiopharmaceutical use, in particular for diagnostic or therapeutic use. More specifically the somatostatin analogue is a receptor-selective somatostatin peptide a...
|
|
WO/2019/243487A1 |
The present invention relates to a somatostatin analogue composition for radiopharmaceutical use, in particular for diagnostic or therapeutic use. More specifically the somatostatin analogue is a receptor-selective somatostatin peptide a...
|
